pharmacoepidemiology

Bidulka, P., Mathur, R., Lugo-Palacios, D. G., O'Neill, S., Basu, A., Silverwood, R. J., et al. (2022). Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment in people with type 2 diabetes in England: a cross-sectional study. Diabetes Obes Metab. http://doi.org/10.1111/dom.14874

View

Eroglu, T. E., Coronel, R., Zuurbier, C. J., Blom, M., de Boer, A., & Souverein, P. C. (2022). Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus. Eur Heart J Cardiovasc Pharmacother. http://doi.org/10.1093/ehjcvp/pvac043

View

Persson, R., Hagberg, K. W., Vasilakis-Scaramozza, C., Yelland, E., Williams, T., Myles, P., & Jick, S. S. (2022). Presence of Codes for Indication for Use in Clinical Practice Research Datalink Aurum: An Assessment of Benign Prostatic Hyperplasia Treatments. Clin Epidemiol, 14, 641-652. http://doi.org/10.2147/clep.s360843

View

van Sloten, T. T., Souverein, P. C., Stehouwer, C. D., & Driessen, J. H. (2022). Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension. J Psychopharmacol, 2698811221082470. http://doi.org/10.1177/02698811221082470

View

Penner, L. S., Gavan, S. P., Ashcroft, D. M., Peek, N., & Elliott, R. A. (2022). Does co-prescribing non-steroidal anti-inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism?. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15371

View

Pradhan, R., Patorno, E., Tesfaye, H., Schneeweiss, S., Yin, H., Franklin, J., et al. (2022). Glucagon-Like Peptide-1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: Multisite Population-Based Cohort Study. Am J Epidemiol. http://doi.org/10.1093/aje/kwac021

View